Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine
Cancer Medicine · 2025-09 · 14 (17)
DOI: 10.1002/cam4.71167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 09.09.2025. Verfasst von Mara M K Veenstra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Nuclear Medicine, Radiopharmaceuticals, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
This review summarizes the role and future prospects of nuclear medicine in ovarian cancer, focusing on novel radiopharmaceuticals beyond FDG for diagnostic, predictive, and therapeutic applications within a theranostic framework. Materials and Methods A narrative literature review was conducted using major databases. Peer‐reviewed articles addressing non‐FDG radiopharmaceuticals in ovarian cancer were identified and assessed; FDG‐based studies were excluded due to the availability of prior comprehensive reviews.
Results
Novel radiopharmaceuticals show potential to enhance diagnostic accuracy, allow early evaluation of treatment response, predict chemotherapy resistance, and support stratification for targeted therapies. Several tracers are under investigation for theranostic use, offering combined diagnostic and therapeutic benefits.
Discussion
Incorporating novel radiopharmaceuticals into ovarian cancer management may help overcome limitations of conventional imaging and systemic therapy. Theranostic strategies, uniting molecular imaging with radionuclide therapy, represent a promising step toward personalized medicine and could significantly influence clinical outcomes.
Conclusion
Nuclear medicine, through innovative radiopharmaceuticals and theranostic approaches beyond FDG, is expected to expand its role in ovarian cancer care. Further research is needed to validate these applications and facilitate their integration into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands.
- Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Erasmus MC Transplant Institute, Rotterdam, the Netherlands.
- Medical Delta, Delft, the Netherlands.
- Department of Medical Oncology, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands.
- Department of Gynaecological Oncology, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands.
ORCID-Profile: Mara M K Veenstra, Ingrid A Boere
Zitieren
APA
Veenstra, M. M. K., van Zanten, S. V., Vegt, E., Boere, I. A., van Beekhuizen, H. J., Nonnekens, J., Verburg, F. A., & Thomeer, M. G. J. (2025). Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine. Cancer Medicine, 14(17). https://doi.org/10.1002/cam4.71167
Vancouver
Veenstra MMK, van Zanten SV, Vegt E, Boere IA, van Beekhuizen HJ, Nonnekens J, et al. Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine. Cancer Medicine. 2025;14(17). doi:10.1002/cam4.71167
BibTeX
@article{Veenstra2025,
author = {Veenstra, Mara M K and van Zanten, Sophie Veldhuijzen and Vegt, Erik and Boere, Ingrid A and van Beekhuizen, Heleen J and Nonnekens, Julie and Verburg, Frederik A and Thomeer, Maarten G J},
title = {Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {17},
doi = {10.1002/cam4.71167}
}
EUVIMED